The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Standard interferon plus ribavirin may leads to higher treatment discontinuation compared with standard interferon alone (low certainty).
The review found no eligible studies for this question.
Standard interferon showed no clear difference in death compared with placebo or control (low certainty).
Standard interferon showed no clear difference in relapse(recurrence after stopping intervention) compared with placebo or control (low certainty).
Standard interferon probably leads to higher end‐of‐treatment response compared with placebo or control (moderate certainty).
Standard interferon showed no clear difference in sustained virological response 6 months after stopping treatment compared with placebo or control (moderate certainty).
Standard interferon showed no clear difference in treatment discontinuation compared with placebo or control (moderate certainty).
Standard interferon showed no clear difference in adverse events compared with placebo or control (moderate certainty).
Pegylated interferon alpha‐2a showed no clear difference in sustained virological response 6 months after stopping treatment compared with standard interferon (low certainty).
Pegylated interferon alpha‐2a showed no clear difference in treatment discontinuation compared with standard interferon (low certainty).
Pegylated interferon alpha‐2a showed no clear difference in adverse events compared with standard interferon (low certainty).
Pegylated interferon alpha‐2a showed no clear difference in death compared with standard interferon (low certainty).
Pegylated interferon alpha‐2a showed no clear difference in relapse(recurrence after stopping) compared with standard interferon (low certainty).
Pegylated interferon alpha‐2a may leads to higher end‐of‐treatment response compared with standard interferon (low certainty).